zolbetuximab,nivolumab
astellas,bms
[]
longer pfs and os with zolbetizumab + mfolfox in cldn18.2+ pts with la or metastatic gastric or gej adenoc in the #spothlight study presented some min ago in #gi23 
Medical Oncologist, GI tumors and NET, @INCMNSZ